News & Updates

In the treatment of ERBB2-positive metastatic breast cancer (MBC), the use of pertuzumab plus trastuzumab alone in the first-line setting and delaying chemotherapy may be a reasonable option for some patients, with the treatment strategy not compromising overall survival (OS) despite a much shorter progression-free survival (PFS), as shown in a study.

Treatment with S-1, an oral fluoropyrimidine formulation similar to capecitabine, plus oxaliplatin (SOX) results in substantial improvements in overall response rate relative to capecitabine plus oxaliplatin (CapeOx) in patients with metastatic colorectal cancer, according to a Philippines study presented at the recent ESMO GI 2023.

Individuals with metabolic syndrome (MetS) have a heightened risk of incident lung cancer, with the risk increase especially pronounced in those with a higher number of metabolic abnormalities and in women, according to a study.

Seventy percent of patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease-related complications, while 59 percent require ≥1 unplanned hospital admission during the course of disease, a study by the Chinese University of Hong Kong (CUHK) has shown.

Hepatic hypoxia-inducible lipid droplet associated protein (HILPDA) is predictive of survival in patients with nonalcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC), according to a study.

Adding camrelizumab to platinum-based chemotherapy in the neoadjuvant treatment setting appears to improve the rate of pathologic complete response (pCR) in Asian patients with stage IIIA or IIIB non–small cell lung cancer (NSCLC), with manageable toxicity, according to data from the phase II TD-FOREKNOW study.

The Whipple procedure, a complex surgery also known as pancreaticoduodenectomy, is the treatment of choice for patients with pancreatic cancer located at the head of the pancreas.